CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Aflibercept

Last Updated: November 16, 2015
Result type: Reports
Project Number: SR0460-000
Product Line: Reimbursement Review

Generic Name: Aflibercept

Brand Name: Eylea

Manufacturer: Bayer Inc.

Therapeutic Area: Macular edema, branch retinal vein occlusion

Indications: Macular edema secondary to branch retinal vein occlusion

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 27, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions